Core Insights - Alamar Biosciences has launched the NULISAseq Neuro 220 Panel, which allows for the multiplexed measurement of 220 biomarkers from a single sample, enhancing early detection capabilities for neurodegenerative diseases [1][2] Group 1: Product Launch and Features - The NULISAseq Neuro 220 Panel expands on the existing NULISAseq CNS Disease Panel 120, incorporating new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson's Research [1][2] - The panel includes a comprehensive collection of Tau protein assays, targeting both brain-derived and peripheral isoforms, making it the largest suite of Tau assays available in a single panel [1][2] - The panel is designed for ultra-high sensitivity and high specificity, ensuring compatibility with non-invasive sample collection devices and supporting pre-symptomatic detection [2][4] Group 2: Research and Development Impact - The launch of the NULISAseq Neuro 220 Panel is expected to raise the standard for neurodegenerative disease research, applicable to a wide range of conditions including Alzheimer's, Parkinson's, and multiple sclerosis [2][4] - The panel facilitates the analysis of disease heterogeneity, detection of co-pathologies, and identification of prognostic or therapeutic response signatures across clinical cohorts [2][4] Group 3: Conference Presentation - The NULISAseq Neuro 220 Panel will be featured at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD 2026) in Copenhagen, Denmark, with data presentations scheduled [3][4] - Dr. Henrik Zetterberg will present data demonstrating the utility of the panel in neurodegenerative diseases during Alamar's product theater on March 18 [3]

Funding and Investment - Alamar Biosciences, Inc. closed an oversubscribed convertible notes financing, raising over $50 million in new capital, with participation from new investors T. Rowe Price Investment Management, Inc. and Braidwell LP, alongside existing investors like Illumina Ventures and Sands Capital [1][2] - The financing will support the commercial advancement of Alamar's precision proteomics platform, aimed at enhancing early disease detection [1][2] Leadership and Board Expansion - Dr. Stephen Williams has been appointed as Chief Scientific Officer, bringing over 30 years of experience in precision medicine and biomarker innovation [7] - Rebecca Chambers and Dr. Frank Witney have been appointed to the board of directors, contributing extensive financial and life sciences leadership experience [8][9] - The leadership team expansion is intended to support Alamar's growth and commitment to operational excellence [6][9] Company Overview - Alamar Biosciences is focused on precision proteomics to enable early disease detection, utilizing proprietary NULISA™ technology and the ARGO™ HT System for ultra-high sensitivity [12]